Risk Factors for Mucormycosis in COVID-19 Patients
Open Access
- 26 September 2021
- journal article
- review article
- Published by Briefland in Jundishapur Journal of Microbiology
- Vol. 14 (8)
- https://doi.org/10.5812/jjm.117435
Abstract
Opportunistic infections, such as mucormycosis, in coronavirus disease 2019 (COVID-19) patients has become a new health challenge. Since opportunistic infections can exacerbate COVID-19 patients' status, it is vital to identify the risk factors to prevent, diagnose, and treat them as soon as possible. Viral, fungal, environmental, and host factors may be responsible for this situation. Long hospital stays, impaired host immune system function due to viral infection, and excessive consumption of glucocorticoids in managing COVID-19 patients are the main risk factors for the increased risk of mucormycosis in COVID-19 patients. Educating health care workers and considering the association between mucormycosis of the paranasal sinuses and different strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the cause of COVID-19 can help prevent invasive fungal sinusitis in COVID-19 patients. Keywords COVID-19 Risk Factor MucormycosisKeywords
This publication has 58 references indexed in Scilit:
- Evaluation and Management of Patients With Isolated NeutropeniaSeminars in Hematology, 2013
- Airborne Fungi in Tabriz, Comparing Airborne and Clinical Samples of A. fumigatus (2011), Survey and Literature ReviewJundishapur Journal of Microbiology, 2013
- Epidemiology and Clinical Manifestations of MucormycosisClinical Infectious Diseases, 2012
- Infections in patients with diabetes mellitus: A review of pathogenesisIndian Journal of Endocrinology and Metabolism, 2012
- Recent Approaches to Antifungal Therapy for Invasive MycosesChemMedChem, 2009
- Zygomycetes Hyphae Trigger an Early, Robust Proinflammatory Response in Human Polymorphonuclear Neutrophils through Toll-Like Receptor 2 Induction but Display Relative Resistance to Oxidative DamageAntimicrobial Agents and Chemotherapy, 2008
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Interferon‐γ and Granulocyte‐Macrophage Colony‐Stimulating Factor Augment the Activity of Polymorphonuclear Leukocytes against Medically Important ZygomycetesThe Journal of Infectious Diseases, 2005
- Mucormycosis in Patients with Renal FailureRenal Failure, 1989
- Adjunctive Hyperbaric Oxygen for Treatment of Rhinocerebral MucormycosisClinical Infectious Diseases, 1988